Media coverage about Biocept (NASDAQ:BIOC) has been trending somewhat positive on Monday, Accern Sentiment reports. The research group identifies negative and positive media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Biocept earned a media sentiment score of 0.25 on Accern’s scale. Accern also gave media coverage about the medical research company an impact score of 45.6880581822026 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Here are some of the news headlines that may have impacted Accern’s analysis:
- Biocept, Inc. (BIOC) registers a price change of -2.40% while Supernus Pharmaceuticals, Inc. (SUPN) finishes with a … – Stocks Gallery (stocksgallery.com)
- Innovation on Circulating Biomarker Market Size, Share, Technology Advances, Professional Survey Report 2017-2022 (sbwire.com)
- Global Circulating Tumor Cell Market is expected to grow at the CAGR of 13.8% during the forecasted period of 2017-2023 (abnewswire.com)
- 5 Medtech Stocks to Steer Clear of Amid Political Chaos – Nasdaq (nasdaq.com)
Shares of Biocept (NASDAQ:BIOC) remained flat at $1.24 during midday trading on Monday. The stock had a trading volume of 81,936 shares. The company’s market capitalization is $37.51 million. The company’s 50 day moving average is $1.28 and its 200 day moving average is $1.56. Biocept has a 1-year low of $0.74 and a 1-year high of $3.39.
Biocept (NASDAQ:BIOC) last issued its quarterly earnings data on Thursday, August 10th. The medical research company reported ($0.21) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.20) by ($0.01). The company had revenue of $1.28 million for the quarter, compared to analyst estimates of $1.23 million. Biocept had a negative return on equity of 550.35% and a negative net margin of 359.48%. On average, equities research analysts anticipate that Biocept will post ($0.79) earnings per share for the current fiscal year.
Several equities analysts recently issued reports on the company. Westpark Capital reissued an “outperform” rating on shares of Biocept in a research note on Thursday, August 3rd. Zacks Investment Research downgraded Biocept from a “hold” rating to a “sell” rating in a report on Wednesday, August 16th. Finally, ValuEngine downgraded Biocept from a “sell” rating to a “strong sell” rating in a report on Friday, September 1st. Two research analysts have rated the stock with a sell rating and three have given a buy rating to the company. Biocept currently has an average rating of “Hold” and an average target price of $2.25.
ILLEGAL ACTIVITY WARNING: This news story was published by Markets Daily and is the sole property of of Markets Daily. If you are accessing this news story on another domain, it was stolen and reposted in violation of United States & international trademark and copyright law. The original version of this news story can be viewed at https://www.themarketsdaily.com/2017/09/26/biocept-bioc-getting-somewhat-favorable-news-coverage-study-shows.html.
Biocept Company Profile
Biocept, Inc is an early commercial-stage molecular oncology diagnostics company. The Company develops and commercializes circulating tumor cell (CTC) and circulating tumor deoxyribonucleic acid (ctDNA), assays utilizing a standard blood sample, or liquid biopsy. The Company’s Target-Selector offering is based on an internally developed, microfluidics-based CTC capture and analysis platform, with enabling features that change how CTC testing can be used by clinicians by providing biomarker detection and monitoring requiring only a standard blood sample.
Receive News & Ratings for Biocept Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biocept Inc. and related companies with MarketBeat.com's FREE daily email newsletter.